The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Hepatitis B Drugs Market Research Report 2024
Synopsis
Global Chronic Hepatitis B Drugs market is projected to reach US$ million in 2030, increasing from US$ million in 2023, with the CAGR of % during the period of 2024 to 2030.
Key companies engaged in the Chronic Hepatitis B Drugs industry include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Chronic Hepatitis B Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Chronic Hepatitis B Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2019-2023) and forecast calculation (2024-2030), aims to help readers to get a comprehensive understanding of global Chronic Hepatitis B Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Nucleos(t)ide Analogues
Interferons
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chronic Hepatitis B Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Chronic Hepatitis B Drugs market is projected to reach US$ million in 2030, increasing from US$ million in 2023, with the CAGR of % during the period of 2024 to 2030.
Key companies engaged in the Chronic Hepatitis B Drugs industry include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical and Hansoh Pharmaceutical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2023.
When refers to consumption region, % value of Chronic Hepatitis B Drugs were sold to North America, Europe and Asia Pacific in 2023. Moreover, China, plays a key role in the whole Chronic Hepatitis B Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2019-2023) and forecast calculation (2024-2030), aims to help readers to get a comprehensive understanding of global Chronic Hepatitis B Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
Bristol Myers Squibb
Gilead Sciences
Novartis
Roche
Merck
Johnson & Johnson
Dawnrays Pharmaceutical
Hansoh Pharmaceutical
Chia Tai-Tianqing Pharmaceutical
Qilu pharmaceutical
Fujian Cosunter Pharma
Xiamen Amoytop Biotech
YaoPharma
Kelun Pharmaceutical
Segment by Type
Nucleos(t)ide Analogues
Interferons
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chronic Hepatitis B Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Hepatitis B Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Nucleos(t)ide Analogues
1.2.3 Interferons
1.3 Market by Application
1.3.1 Global Chronic Hepatitis B Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Hepatitis B Drugs Market Perspective (2019-2030)
2.2 Chronic Hepatitis B Drugs Growth Trends by Region
2.2.1 Global Chronic Hepatitis B Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Hepatitis B Drugs Historic Market Size by Region (2019-2024)
2.2.3 Chronic Hepatitis B Drugs Forecasted Market Size by Region (2025-2030)
2.3 Chronic Hepatitis B Drugs Market Dynamics
2.3.1 Chronic Hepatitis B Drugs Industry Trends
2.3.2 Chronic Hepatitis B Drugs Market Drivers
2.3.3 Chronic Hepatitis B Drugs Market Challenges
2.3.4 Chronic Hepatitis B Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Hepatitis B Drugs Players by Revenue
3.1.1 Global Top Chronic Hepatitis B Drugs Players by Revenue (2019-2024)
3.1.2 Global Chronic Hepatitis B Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Hepatitis B Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Hepatitis B Drugs Revenue
3.4 Global Chronic Hepatitis B Drugs Market Concentration Ratio
3.4.1 Global Chronic Hepatitis B Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Hepatitis B Drugs Revenue in 2023
3.5 Chronic Hepatitis B Drugs Key Players Head office and Area Served
3.6 Key Players Chronic Hepatitis B Drugs Product Solution and Service
3.7 Date of Enter into Chronic Hepatitis B Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Hepatitis B Drugs Breakdown Data by Type
4.1 Global Chronic Hepatitis B Drugs Historic Market Size by Type (2019-2024)
4.2 Global Chronic Hepatitis B Drugs Forecasted Market Size by Type (2025-2030)
5 Chronic Hepatitis B Drugs Breakdown Data by Application
5.1 Global Chronic Hepatitis B Drugs Historic Market Size by Application (2019-2024)
5.2 Global Chronic Hepatitis B Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Hepatitis B Drugs Market Size (2019-2030)
6.2 North America Chronic Hepatitis B Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Hepatitis B Drugs Market Size by Country (2019-2024)
6.4 North America Chronic Hepatitis B Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Hepatitis B Drugs Market Size (2019-2030)
7.2 Europe Chronic Hepatitis B Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Hepatitis B Drugs Market Size by Country (2019-2024)
7.4 Europe Chronic Hepatitis B Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Hepatitis B Drugs Market Size (2019-2030)
8.2 Asia-Pacific Chronic Hepatitis B Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Hepatitis B Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Hepatitis B Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Hepatitis B Drugs Market Size (2019-2030)
9.2 Latin America Chronic Hepatitis B Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Hepatitis B Drugs Market Size by Country (2019-2024)
9.4 Latin America Chronic Hepatitis B Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Hepatitis B Drugs Market Size (2019-2030)
10.2 Middle East & Africa Chronic Hepatitis B Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Hepatitis B Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Hepatitis B Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Hepatitis B Drugs Introduction
11.1.4 GSK Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Chronic Hepatitis B Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Detail
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Chronic Hepatitis B Drugs Introduction
11.3.4 Gilead Sciences Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.3.5 Gilead Sciences Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Hepatitis B Drugs Introduction
11.4.4 Novartis Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Chronic Hepatitis B Drugs Introduction
11.5.4 Roche Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Chronic Hepatitis B Drugs Introduction
11.6.4 Merck Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Chronic Hepatitis B Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Dawnrays Pharmaceutical
11.8.1 Dawnrays Pharmaceutical Company Detail
11.8.2 Dawnrays Pharmaceutical Business Overview
11.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Drugs Introduction
11.8.4 Dawnrays Pharmaceutical Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.8.5 Dawnrays Pharmaceutical Recent Development
11.9 Hansoh Pharmaceutical
11.9.1 Hansoh Pharmaceutical Company Detail
11.9.2 Hansoh Pharmaceutical Business Overview
11.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Drugs Introduction
11.9.4 Hansoh Pharmaceutical Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.9.5 Hansoh Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing Pharmaceutical
11.10.1 Chia Tai-Tianqing Pharmaceutical Company Detail
11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview
11.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Drugs Introduction
11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development
11.11 Qilu pharmaceutical
11.11.1 Qilu pharmaceutical Company Detail
11.11.2 Qilu pharmaceutical Business Overview
11.11.3 Qilu pharmaceutical Chronic Hepatitis B Drugs Introduction
11.11.4 Qilu pharmaceutical Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.11.5 Qilu pharmaceutical Recent Development
11.12 Fujian Cosunter Pharma
11.12.1 Fujian Cosunter Pharma Company Detail
11.12.2 Fujian Cosunter Pharma Business Overview
11.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Drugs Introduction
11.12.4 Fujian Cosunter Pharma Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.12.5 Fujian Cosunter Pharma Recent Development
11.13 Xiamen Amoytop Biotech
11.13.1 Xiamen Amoytop Biotech Company Detail
11.13.2 Xiamen Amoytop Biotech Business Overview
11.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Drugs Introduction
11.13.4 Xiamen Amoytop Biotech Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.13.5 Xiamen Amoytop Biotech Recent Development
11.14 YaoPharma
11.14.1 YaoPharma Company Detail
11.14.2 YaoPharma Business Overview
11.14.3 YaoPharma Chronic Hepatitis B Drugs Introduction
11.14.4 YaoPharma Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.14.5 YaoPharma Recent Development
11.15 Kelun Pharmaceutical
11.15.1 Kelun Pharmaceutical Company Detail
11.15.2 Kelun Pharmaceutical Business Overview
11.15.3 Kelun Pharmaceutical Chronic Hepatitis B Drugs Introduction
11.15.4 Kelun Pharmaceutical Revenue in Chronic Hepatitis B Drugs Business (2019-2024)
11.15.5 Kelun Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
